These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 29367723)

  • 41. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function.
    Sambhara S; Kurichh A; Miranda R; Tumpey T; Rowe T; Renshaw M; Arpino R; Tamane A; Kandil A; James O; Underdown B; Klein M; Katz J; Burt D
    Cell Immunol; 2001 Aug; 211(2):143-53. PubMed ID: 11591118
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Emerging influenza viruses and the prospect of a universal influenza virus vaccine.
    Krammer F
    Biotechnol J; 2015 May; 10(5):690-701. PubMed ID: 25728134
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The quest for a nanoparticle-based vaccine inducing broad protection to influenza viruses.
    Bolduc M; Baz M; Laliberté-Gagné MÈ; Carignan D; Garneau C; Russel A; Boivin G; Savard P; Leclerc D
    Nanomedicine; 2018 Nov; 14(8):2563-2574. PubMed ID: 30193813
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Immunogenicity of recombinant proteins including ectodomain of M2 influenza virus A].
    Stepanova LA; Kovaleva AA; Potapchuk MV; Korotkov AV; Kupriianov VV; Blokhina EA; Kotliarov RIu; Tsybalova LM
    Vopr Virusol; 2013; 58(3):21-5. PubMed ID: 24006628
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies.
    De Filette M; Martens W; Smet A; Schotsaert M; Birkett A; Londoño-Arcila P; Fiers W; Saelens X
    Vaccine; 2008 Dec; 26(51):6503-7. PubMed ID: 18835315
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Universal influenza virus vaccines and therapeutic antibodies.
    Nachbagauer R; Krammer F
    Clin Microbiol Infect; 2017 Apr; 23(4):222-228. PubMed ID: 28216325
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Vaccine options for influenza: thinking small.
    Schepens B; De Vlieger D; Saelens X
    Curr Opin Immunol; 2018 Aug; 53():22-29. PubMed ID: 29631195
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
    Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vaccination with soluble headless hemagglutinin protects mice from challenge with divergent influenza viruses.
    Wohlbold TJ; Nachbagauer R; Margine I; Tan GS; Hirsh A; Krammer F
    Vaccine; 2015 Jun; 33(29):3314-21. PubMed ID: 26026378
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Broadly protective influenza vaccines: design and production platforms.
    Elbahesh H; Saletti G; Gerlach T; Rimmelzwaan GF
    Curr Opin Virol; 2019 Feb; 34():1-9. PubMed ID: 30497050
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A virus-like particle vaccine candidate for influenza A virus based on multiple conserved antigens presented on hepatitis B tandem core particles.
    Ramirez A; Morris S; Maucourant S; D'Ascanio I; Crescente V; Lu IN; Farinelle S; Muller CP; Whelan M; Rosenberg W
    Vaccine; 2018 Feb; 36(6):873-880. PubMed ID: 29306508
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Eliciting broadly protective antibody responses against influenza.
    Kirchenbaum GA; Ross TM
    Curr Opin Immunol; 2014 Jun; 28():71-6. PubMed ID: 24632083
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chimeric Hemagglutinin-Based Influenza Virus Vaccines Induce Protective Stalk-Specific Humoral Immunity and Cellular Responses in Mice.
    Choi A; Bouzya B; Cortés Franco KD; Stadlbauer D; Rajabhathor A; Rouxel RN; Mainil R; Van der Wielen M; Palese P; García-Sastre A; Innis BL; Krammer F; Schotsaert M; Mallett CP; Nachbagauer R
    Immunohorizons; 2019 Apr; 3(4):133-148. PubMed ID: 31032479
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Matrix-M Adjuvated Seasonal Virosomal Influenza Vaccine Induces Partial Protection in Mice and Ferrets against Avian H5 and H7 Challenge.
    Cox F; Roos A; Hafkemeijer N; Baart M; Tolboom J; Dekking L; Stittelaar K; Goudsmit J; Radošević K; Saeland E
    PLoS One; 2015; 10(9):e0135723. PubMed ID: 26402787
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection.
    Schmitz N; Beerli RR; Bauer M; Jegerlehner A; Dietmeier K; Maudrich M; Pumpens P; Saudan P; Bachmann MF
    Eur J Immunol; 2012 Apr; 42(4):863-9. PubMed ID: 22531913
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Human Monoclonal Antibody 81.39a Effectively Neutralizes Emerging Influenza A Viruses of Group 1 and 2 Hemagglutinins.
    Marjuki H; Mishin VP; Chai N; Tan MW; Newton EM; Tegeris J; Erlandson K; Willis M; Jones J; Davis T; Stevens J; Gubareva LV
    J Virol; 2016 Dec; 90(23):10446-10458. PubMed ID: 27630240
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mini-HA Is Superior to Full Length Hemagglutinin Immunization in Inducing Stem-Specific Antibodies and Protection Against Group 1 Influenza Virus Challenges in Mice.
    van der Lubbe JEM; Verspuij JWA; Huizingh J; Schmit-Tillemans SPR; Tolboom JTBM; Dekking LEHA; Kwaks T; Brandenburg B; Meijberg W; Zahn RC; Roozendaal R; Kuipers H
    Front Immunol; 2018; 9():2350. PubMed ID: 30369928
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Implications of broadly neutralizing antibodies in the development of a universal influenza vaccine.
    Cho A; Wrammert J
    Curr Opin Virol; 2016 Apr; 17():110-115. PubMed ID: 27031684
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Elicitation of Protective Antibodies against 20 Years of Future H3N2 Cocirculating Influenza Virus Variants in Ferrets Preimmune to Historical H3N2 Influenza Viruses.
    Allen JD; Jang H; DiNapoli J; Kleanthous H; Ross TM
    J Virol; 2019 Feb; 93(3):. PubMed ID: 30429350
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection.
    El Bakkouri K; Descamps F; De Filette M; Smet A; Festjens E; Birkett A; Van Rooijen N; Verbeek S; Fiers W; Saelens X
    J Immunol; 2011 Jan; 186(2):1022-31. PubMed ID: 21169548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.